« Return to News | Awards & Advancement

DIA Appoints New Worldwide Executive Director

Thursday, September 10, 2009 06:27 AM

The Drug Information Association (DIA) appointed Paul Pomerantz as its new worldwide executive director, replacing William Brassington who has served as acting executive director since July 2008.

Pomerantz is currently executive vice president of the American Society of Plastic Surgeons, an association of more than 7,000 reconstructive and cosmetic plastic surgeons, and will transition to his new role at DIA as of December 1.

Pomerantz will direct the association’s global operations and strategic expansion, while Brassington resumes his role as DIA’s worldwide director of finance.

“The requirements for the position of DIA worldwide executive director have evolved and are particularly challenging,” said Marie Dray, DIA immediate-past president and search chair of the search committee that hired Pomerantz, in a statement. “The position requires experience as an association leader, understanding of the challenges of membership building, skill in training and educational program development, not to mention state-of-the-art knowledge of global healthcare changes.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.